Uterine Fibroids Research Study

AbbVie Research Study – Participants Needed

We are participating with AbbVie pharmaceuticals in a research study as it relates to uterine fibroids and heavy vaginal bleeding in women. In this study, patients will be given Elagolix, an oral hormonal medication shown to reduce undesired symptoms of fibroids, as well as to decrease fibroid size.  This approach is much less invasive than current leading fibroid treatment and does not pose a negative consequence on future fertility.

In the study, approximately 100 women from around the US, Canada, and Puerto Rico willbe
administered different doses of Elagolix.  FIH, along with all the other participating facilities, will be monitoring the progress of their patients.  The outcome of this study will expand our understanding of the ideal dosage and effects of this medication.

Participants will receive complimentary treatment as well as debit card compensation.  If you think you or someone you know might be a good candidate, please contact the Study Coordinator, Joycelyn, at 808-380-8234 or joycelyn@armghawaii.com.

Back to blog home

Latest News & Events

February 21, 2023

Best of Hawaii Viewer’s Choice Award

Read More

August 15, 2023

Ask the Docs June 2024: FIH’s New Office!

Read More


Fertility Institute of Hawaii Named One of the Nation’s Top Fertility Clinics by Healthcare Business Review

Read More

June 3, 2024

Ask the Docs May 2024: National Military Awareness Month

Read More